Although there is as yet no evidence that hypertension is related to outcomes of COVID-19, or that ACE inhibitor or ARB use is harmful, or for that matter beneficial, during the COVID-19 pandemic, ACE inhibitors and ARBs could diminish the potential for development of either acute respiratory distress syndrome, myocarditis or acute kidney injury, which can occur in COVID-19 patients. In fact, ARBs have been suggested as a treatment for COVID-19 and its complications. Using recombinant ACE2 could be a therapeutic approach in COVID-19 to reducing viral load by binding circulating SARS-CoV-2 viral particles and reducing their potential attachment to tissue ACE2. None of these possibilities have however been demonstrated in patients yet.